The Biostatistics Core Component is designed to support the Research Projects and other Core Components of the Ovarian Cancer Program Project with study design and data analysis. The Biostatistics Core represents a highly experienced group of biostatisticians who are familiar with the statistical methods applicable to a wide variety of data sets. They have worked with the investigators of the various Research Projects through their prior participation in the Program Project and in other settings. They have participated in the design of previous gynecologic oncology clinical trials and in research studies including retrospective prognostic factor analyses, epidemiology, and basic research projects involving in vitro and animal models and imaging. Dr. Thaler also serves on the Quality of Life Committee of the Gynecolgical Oncology Group. Thus, the Biostatistics Core will be able to provide all levels of support to the different projects described in this grant application. The Biostatistics faculty participating in the Program Project have the expertise to perform the broad range of statistical services necessary for the wide variety of proposed studies. The biostatisticians will also be available to Program Project investigators running the Core Components to provide statistical advice and support. The members of the Biostatistics Core have full access to the MSKCC Department of Epidemiology and Biostatistics'state-of-the art computing facilities, database management and statistical analysis software to perform all the required functions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA052477-17
Application #
7902228
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-05-01
Budget End
2010-04-30
Support Year
17
Fiscal Year
2009
Total Cost
$230,750
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Grisham, Rachel N; Sylvester, Brooke E; Won, Helen et al. (2015) Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. J Clin Oncol 33:4099-105
Rao, Thapi D; Tian, Huasong; Ma, Xun et al. (2015) Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. PLoS One 10:e0126633
Tew, William P; Colombo, Nicoletta; Ray-Coquard, Isabelle et al. (2014) Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. Cancer 120:335-43
Tsuji, Takemasa; Sabbatini, Paul; Jungbluth, Achim A et al. (2013) Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res 1:340-50
Hyman, David M; Zhou, Qin; Iasonos, Alexia et al. (2012) Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 118:3703-9
Marchini, Sergio; Poynor, Elizabeth; Barakat, Richard R et al. (2012) The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer. Clin Cancer Res 18:4313-24
Iasonos, Alexia; Sabbatini, Paul; Spriggs, David R et al. (2012) Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission. Int J Gynecol Cancer 22:63-9
Soslow, Robert A; Han, Guangming; Park, Kay J et al. (2012) Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 25:625-36
Blixt, Ola; Lavrova, Olga I; Mazurov, Dmitriy V et al. (2012) Analysis of Tn antigenicity with a panel of new IgM and IgG1 monoclonal antibodies raised against leukemic cells. Glycobiology 22:529-42
Gardner, Ginger J; Baser, Raymond E; Brady, Mark F et al. (2012) CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study. Gynecol Oncol 124:216-20

Showing the most recent 10 out of 109 publications